The National Task Force of the Union Ministry of Health constituted for the corona epidemic, has decided to exclude tocilizumab medicine from the treatment of this epidemic. In the past, the Drug Controller had allowed its limited use in emergency situations in the treatment of Corona patients.
Keeping in mind the medical needs in the treatment of corona infection, the Controller General of India (DCGI) approved the limited use of the Biocon drug ‘ibalizumab’ used in the treatment of dermatitis in the treatment of those patients with corona, Those who have difficulty in breathing from moderate to severe.
Official sources said that the meeting of the National Task Force on Friday discussed the inclusion of this drug in the treatment of corona patients in hospitals. Most members of the task force believed that so far there was not enough evidence in favor of this drug to be included in the treatment of ISA Corona patients.
Earlier, the Union Health Ministry had reported that domestic biopharmaceutical company Biocon has been manufacturing and marketing this drug since 2013 under the brand name Alzumab. Let it be said that tocilizumab injection is a drug used to treat skin disease psoriasis. This drug is made by the Bangalore-based pharmaceutical company Biocon Ltd.
Recently the ICMR and AIIMS had asked all the states to use it in the treatment of the mild case of corona. At the same time, while advising caution in the use of the much-hyped medicine like Remadecivir, he had also cautioned against its side effects on liver and kidney.
About Post Author
